Neurocrine Biosciences (NBIX) Misses Q4 EPS by 54c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $138.40 -0.39%
Revenue Growth %: +30.8%
Financial Fact:
Total operating expenses: 38.44M
Today's EPS Names:
OCCI, IPX, ALZN, More
Revenue Growth %: +30.8%
Financial Fact:
Total operating expenses: 38.44M
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.04, $0.54 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $303.5 million versus the consensus estimate of $320 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
- BMS Zenbexus doubles response rates in myeloma trial
- This Is The Top REIT Stock Stifel Analysts Are Backing Right Now
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
